JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.

@article{Arts2009JNJ26481585AN,
  title={JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.},
  author={Janine Arts and Peter J. H. King and Ann Mari{\"e}n and Wim Floren and A. J. C. Beli{\"e}n and Lut Janssen and Isabelle Pilatte and Bruno Roux and Laurence Decrane and Ron A. H. J. Gilissen and Ian D. Hickson and Veronique Vreys and Eug{\`e}ne H. Cox and Kees Bol and Willem Talloen and Ilse Goris and Luc J. Andries and Marc Du Jardin and Michel Janicot and Martin A. Page and Kristof van Emelen and Patrick Angibaud},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 22},
  pages={6841-51}
}
PURPOSE Histone deacetylase (HDAC) inhibitors have shown promising clinical activity in the treatment of hematologic malignancies, but their activity in solid tumor indications has been limited. Most HDAC inhibitors in clinical development only transiently induce histone acetylation in tumor tissue. Here, we sought to identify a "second-generation" class I HDAC inhibitor with prolonged pharmacodynamic response in vivo, to assess whether this results in superior antitumoral efficacy… CONTINUE READING